At 12.9% CAGR, the Asia Pacific Aortic Valve Replacement Devices Market is Projected to be Worth US$ 3,489.38 million by 2030, says The Business Market Insights

According to the Business Market Insights’ research, the Asia Pacific aortic valve replacement devices market was valued at US$ 1,323.15 million in 2022 and is expected to reach US$ 3,489.38 million by 2030, registering a CAGR of 12.9% from 2022 to 2030. Rising number of aortic valve replacement surgeries and increasing demand for minimally invasive techniques are among the critical factors attributed to the Asia Pacific aortic valve replacement devices market expansion.                     

The increasing demand for minimally invasive techniques in aortic valve replacement surgeries reflects a significant shift in medical practice and patient preferences. In a minimally invasive aortic valve replacement, a poorly working aortic valve is replaced with an artificial valve. This trend is driven by the desire to minimize the invasiveness of procedures, reduce the associated risks, and promote faster recovery times. Minimally invasive approaches typically involve smaller incisions and the use of specialized instruments and technologies to access the heart, which can lead to shorter hospital stays and less scarring. Moreover, patients often experience less pain and a quicker return to their daily activities. Surgeons have embraced these techniques due to their potential benefits, and advancements in medical devices and surgical skills have further facilitated widespread adoption. As a result, healthcare institutions are investing in training their medical teams and acquiring the necessary equipment to meet the increasing demand for minimally invasive aortic valve replacement surgeries, thereby providing patients with improved treatment options and enhanced overall healthcare experiences.

On the contrary, product recalls hurdle the growth of Asia Pacific aortic valve replacement devices market.

Based on product, the Asia Pacific aortic valve replacement devices market is segmented into sutureless valve and mechanical valve. The sutureless valve segment held 62.7% share of Asia Pacific aortic valve replacement devices market in 2022, amassing US$ 829.36 million. It is projected to garner US$ 2,262.18 million by 2030 to expand at 13.4% CAGR during 2022–2030.

Based on surgery, the Asia Pacific aortic valve replacement devices market is segmented into minimally invasive surgery and open surgery. The minimally invasive surgery segment held 75.6% share of Asia Pacific aortic valve replacement devices in 2022, amassing US$ 1,000.39 million. It is projected to garner US$ 2,742.01 million by 2030 to expand at 13.4% CAGR during 2022–2030.  

Based on end user, the Asia Pacific aortic valve replacement devices market is segmented into hospitals & clinics, ambulatory surgical centers, and others. The hospitals & clinics segment held 66.7% share of Asia Pacific aortic valve replacement devices market in 2022, amassing US$ 882.92 million. It is projected to garner US$ 2,399.56 million by 2030 to expand at 13.3% CAGR during 2022–2030.

Based on country, the Asia Pacific aortic valve replacement devices market has been categorized into China, India, Japan, Australia, South Korea, and the Rest of Asia Pacific.  Our regional analysis states that China captured 24.1% share of Asia Pacific aortic valve replacement devices market in 2022. It was assessed at US$ 318.75 million in 2022 and is likely to hit US$ 851.76 million by 2030, exhibiting a CAGR of 13.1% during 2022–2030.      

Key players operating in the Asia Pacific aortic valve replacement devices market are Abbott Laboratories, Artivion Inc, Boston Scientific Corp, Edwards Lifesciences Corp, LivaNova Plc, Medtronic Plc, and Venus MedTech HangZhou Inc, among others.   

• In May 2023, Edwards Lifesciences announced new data from the COMMENCE aortic trial, demonstrating low structural valve deterioration (SVD) rates in bioprosthetic aortic valves with the company's innovative RESILIA tissue. The data, representing the longest clinical follow-up for Edwards' bioprosthetic surgical aortic valve with RESILIA tissue with a mean follow-up of 7.7 years, were presented at the 103rd annual meeting of the American Association for Thoracic Surgery.    
• In Feb 2023, Medtronic relaunched its Harmony Transcatheter Pulmonary Valve (TPV) System, a minimally invasive alternative to open-heart surgery for congenital heart disease patients with native or surgically repaired right ventricular outflow tract (RVOT).

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com